Painful bladder syndrome/interstitial cystitis.

Urogynaecologist, Monash Medical Centre, 13 Brunswick St, Fitzroy, Vic. 3065, Australia.
Bailli&egrave re s Best Practice and Research in Clinical Obstetrics and Gynaecology (Impact Factor: 2.02). 01/2006; 19(6):843-59. DOI: 10.1016/j.bpobgyn.2005.08.004
Source: PubMed

ABSTRACT Painful bladder syndrome (PBS) is the term used to refer to a chronic symptom complex of urinary frequency and bladder 'pressure', discomfort or pain in the absence of any other reasonable cause for these symptoms (such as infection). Interstitial cystitis (IC) is the established term used by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) consensus workshop for which a research definition was formulated in the late 1980s. Opinion varies regarding not only definition but also the usefulness of diagnostic investigations such as urodynamic assessment and the potassium sensitivity test. There are still controversies concerning the most basic investigation of cystoscopy in PBS/IC. New developments in the study of PBS/IC include the identification of a potential urinary biomarker, antiproliferative factor (APF), which is produced by urothelial cells in IC and thought to inhibit proliferation. In addition, condition-specific validated questionnaires should aid evaluation, and a growing number of randomised controlled trials should enable clinicians to use evidence-based therapeutic options.

  • [Show abstract] [Hide abstract]
    ABSTRACT: For years the bladder epithelium has been the focus for diagnosing and treating the frequency, urgency, and pelvic pain of interstitial cystitis. However, many patients have not found symptom relief with these therapies. Pelvic floor dysfunction is often present in these patients, yet it is often untreated. Pelvic floor dysfunction may be related to abuse, past surgeries, or other causes. It is important to look outside of the bladder and explore other causes and treatments for this condition. Pelvic floor therapies should be a first line of treatment for those women with chronic pelvic pain related to pelvic floor dysfunction.
    Current Urology Reports 12/2006; 7(6):450-5.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Terminology for lower urinary tract symptoms has been popularized since an extensive revision by the International Continence Society (ICS) in 2002, however the revision incurred significant confusion and inconvenience among the users. For example, distinction between night time frequency and nocturia is practically infeasible; urgency must be of sudden onset (persistent urgency is an invalid usage); terms are lacking for some types of urinary leakage; bladder filling and urge to void must be differentiated; symptom syndromes are not applicable to non-functional abnormality; a syndrome for bladder hypersensitivity is lacking; polyuria is not defined properly. This review has detailed definitions and confusions related to the latest version, and suggested possible solutions for a better vocabulary of words.
    International Journal of Urology 02/2008; 15(1):35-43. · 1.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The urinary bladder has certain unique anatomical features which enable it to form an effective barrier to toxic substances diffusing from the urine into the blood. The barrier function is due to the epithelial surface of the urinary bladder, the urothelium, which has characteristic umbrella cells, joined by tight junctions and covered by impenetrable plaques, as well as an anti-adherent mucin layer. Diseases of the urinary bladder, such as bladder carcinomas and interstitial cystitis, cause acute damage to the bladder wall and cannot be effectively treated by systemic administration of drugs. Such conditions may benefit from intravesical drug delivery (IDD), which involves direct instillation of drug into the bladder via a catheter, to attain high local concentrations of the drug with minimal systemic effects. IDD however has its limitations, since the permeability of the urothelial layer is very low and instilled drug solutions become diluted with urine and get washed out of the bladder during voiding, necessitating repeated infusions of the drug. Permeation enhancers serve to overcome these problems to some extent by using electromotive force to enhance diffusion of the drug into the bladder wall or chemical molecules, such as chitosan, dimethylsulphoxide, to temporarily disrupt the tight packing of the urothelium. Nanotechnology can be integrated with IDD to devise drug-encapsulated nanoparticles that can greatly improve chemical interactions with the urothelium and enhance penetration of drugs into the bladder wall. Nanocarriers such as liposomes, gelatin nanoparticles, polymeric nanoparticles and magnetic particles, have been found to enhance local drug concentrations in the bladder as well as target diseased cells. Intravesical drug carriers can be further improved by using mucoadhesive biomaterials which are strongly adhered to the urothelial cell lining, thus preventing the carrier from being washed away during urine voiding. This increases the residence time of the drug at the target site and enables sustained delivery of the drug over a prolonged time span. Polymeric hydrogels, such as the temperature sensitive PEG-PLGA-PEG polymer, have been used to develop in situ gelling systems to deliver drugs into the bladder cavity. Recent advances and future prospects of biodegradable nanocarriers and in situ gels as drug delivery agents for intravesical drug delivery are reviewed in this paper.
    Journal of Controlled Release 12/2010; 148(2):147-59. · 7.63 Impact Factor